Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00789360 · ClinicalTrials.gov registry record · Phase 1

Staccato Loxapine Pulmonary Safety in Healthy Volunteers

A Phase 1 study, sponsored by Alexza Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target

NCT00789360 is a Phase 1 study that has completed, run by Alexza Pharmaceuticals. The registered enrollment target is 30 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00789360, a Phase 1 study, has completed, sponsored by Alexza Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target

Study Summary

The objective of this trial is to assess the pulmonary safety of 2 inhaled doses of Staccato Loxapine within a day.

Interventions

  • DRUG Inhaled Placebo
  • DRUG Inhaled Loxapine

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2008-11
Est. Completion 2009-04
Phase Phase 1

Sponsor

Alexza Pharmaceuticals

22 total trials

What the Registry Record Tells You About NCT00789360

The ClinicalTrials.gov registry entry for NCT00789360 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexza Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Inhaled Placebo is the first listed.

NCT00789360 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00789360 about?

NCT00789360 is a clinical study titled "Staccato Loxapine Pulmonary Safety in Healthy Volunteers". The objective of this trial is to assess the pulmonary safety of 2 inhaled doses of Staccato Loxapine within a day.

What is the current status of trial NCT00789360?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2008-11. Estimated completion is 2009-04.

What interventions are being tested in trial NCT00789360?

The interventions under investigation include: Inhaled Placebo (DRUG), Inhaled Loxapine (DRUG).

Who is sponsoring clinical trial NCT00789360?

This trial is sponsored by Alexza Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.